Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the ...
AbbVie Inc. raised its full-year profit forecast after quarterly results beat estimates, a sign of confidence amid growing ...
New data show early and sustained weight loss with atogepant, raising the possibility of metabolic benefits beyond migraine prevention.
Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA ...
P004 represents a first-in-class application of GLP-1 receptor agonism in the intra-articular space, specifically targeting patients with knee osteoarthritis and synovitis who have failed multiple ...
The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results